Impact of Fc-gamma receptor IIIA polymorphism on late-onset neutropenia and clinical outcomes in kidney transplant recipients following rituximab induction therapy
Clinical and Experimental Nephrology · 2025
DOI: 10.1007/s10157-024-02610-7 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Experimental Nephrology, 2025. Verfasst von Yuki Tashiro und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Urology, Kobe University Graduate School of Medicine, 7-5-2 Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan. Hauptthemen laut MEDLINE: Kidney Transplantation, Rituximab, Receptors, IgG, Neutropenia. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Kobe University.
Abstract (Originalsprache)
Background
This study aimed to investigate the association between the Fc-gamma receptor IIIA (FCGR3A) 158 polymorphism and clinical outcomes in kidney transplantation (KTx) patients. Specifically, we focused on late-onset neutropenia (LON) in ABO-incompatible (ABOi) or HLA-incompatible (HLAi) KTx recipients who underwent rituximab (RTx) desensitization therapy.
Methods
FCGR3A 158F/V polymorphisms were identified in 85 ABOi or HLAi KTx recipients who underwent RTx desensitization at our institution between April 2008 and October 2021. We analyzed these polymorphism groups in relation to their preoperative background and incidence of LON, infection, and rejection. In addition, we examined the risk factors for LON development.
Results
The following FCGR3A 158F/V polymorphisms were identified: FF genotype ( n = 45); FV genotype ( n = 36), and VV genotype ( n = 4). LON occurred in 25 out of 85 recipients within 1 year after KTx, significantly more frequently in patients with the FCGR3A FV + VV genotype (17/40) than in those with the FF genotype (8/45) ( p = 0.01). A multivariate analysis identified the V-allele as an independent risk factor for LON (OR, 4.03; 95% CI, 1.38—11.73, p = 0.01). However, there were no significant differences in the incidence rates of post-transplant infection and rejection between the FF and FV + VV genotypes.
Conclusion
Recipients with the FCGR3A 158 V-allele were identified as having a higher risk of developing LON following KTx with RTx desensitization therapy. However, the presence of this V-allele did not affect the safety or efficacy of RTx desensitization before KTx.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Urology, Kobe University Graduate School of Medicine, 7-5-2 Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan.
- Division of Urology, Kobe University Graduate School of Medicine, 7-5-2 Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan. yhyodo@med.kobe-u.ac.jp.
- Department of Urology, Hyogo Prefectural Amagasaki General Medical Center, Amagasaki, Hyogo, Japan.
Förderung
- Kobe University
Zitieren
APA
Tashiro, Y., Hyodo, Y., Kitamura, S., Fujimoto, T., Endo, T., Nishioka, S., Yokoyama, N., Hara, T., Chiba, K., & Miyake, H. (2025). Impact of Fc-gamma receptor IIIA polymorphism on late-onset neutropenia and clinical outcomes in kidney transplant recipients following rituximab induction therapy. Clinical and Experimental Nephrology. https://doi.org/10.1007/s10157-024-02610-7
Vancouver
Tashiro Y, Hyodo Y, Kitamura S, Fujimoto T, Endo T, Nishioka S, et al. Impact of Fc-gamma receptor IIIA polymorphism on late-onset neutropenia and clinical outcomes in kidney transplant recipients following rituximab induction therapy. Clinical and Experimental Nephrology. 2025. doi:10.1007/s10157-024-02610-7
BibTeX
@article{Tashiro2025,
author = {Tashiro, Yuki and Hyodo, Yoji and Kitamura, Satoshi and Fujimoto, Takuya and Endo, Takahito and Nishioka, Shun and Yokoyama, Naoki and Hara, Takuto and Chiba, Koji and Miyake, Hideaki},
title = {Impact of Fc-gamma receptor IIIA polymorphism on late-onset neutropenia and clinical outcomes in kidney transplant recipients following rituximab induction therapy},
journal = {Clinical and Experimental Nephrology},
year = {2025},
doi = {10.1007/s10157-024-02610-7}
}
EUVIMED